Asset Details
Do you wish to reserve the book?
Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study
Do you wish to request the book?
Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study
2026
Overview
A subset of patients with severe asthma (SA) has normal lung function, defined by a pre-bronchodilator (BD) forced expiratory volume in 1 second (FEV
1
) of ≥80% of predicted normal value. The effect of biologic treatments on patients with SA and normal lung function is not well understood. This analysis assessed the effectiveness of biologics among adults with SA and normal lung function using data from CHRONICLE (NCT03373045), a real-world observational study of United States patients with SA. Among the 233 patients in this analysis, 28.8% (
n
=67) had normal lung function, whereas 71.2% (
n
=166) had reduced lung function (pre-BD FEV
1
<80% of predicted normal). In the 12 months before initiating biologic treatment, annualized exacerbation rates were 1.19 (95% confidence interval [CI]: 0.95–1.49) in patients with normal lung function and 1.42 (95% CI: 1.24–1.61) in those with reduced lung function. Exacerbation rates were reduced by 50% (
p
<0.0001) and by 59% (
p
<0.0001) among those with normal and reduced lung function, respectively. Rates of exacerbation-related emergency department (ED) visits in the 12 months before initiating biologic treatment in patients with normal lung function and reduced lung function were 0.18 (95% CI: 0.09–0.31) and 0.38 (95% CI: 0.29–0.49), respectively. The rate of exacerbation-related ED visits was reduced by 44% (
p
=0.03) and 63% (
p
<0.0001) among those with normal and reduced lung function, respectively. Biologic treatments showed similar effectiveness in reducing exacerbations and exacerbation-related ED visits in patients with SA and normal lung function compared with patients with reduced lung function.
Clinical trial registration
ClinicalTrials.gov identifier: NCT03373045.
Publisher
BioMed Central,BioMed Central Ltd,Nature Publishing Group,BMC
Subject
/ Aged
/ Anti-Asthmatic Agents - therapeutic use
/ Asthma
/ Biological Products - therapeutic use
/ Female
/ Forced Expiratory Volume - drug effects
/ Forced Expiratory Volume - physiology
/ Humans
/ Lungs
/ Male
/ Medicine
/ Patients
/ Pneumology/Respiratory System
/ Respiratory Function Tests - methods
/ Steroids
